MediciNova Inc., a biopharmaceutical company listed on the NASDAQ and the Tokyo Stock Exchange, has provided an update on the enrollment status of two major clinical trials involving its developmental compounds MN-166 (ibudilast) and MN-001 (tipelukast). The ongoing Phase 2/3 COMBAT-ALS trial is nearing completion with only a single digit number of patients remaining to be randomized. In parallel, the Phase 2 trial targeting dyslipidemia and fatty liver disease in type 2 diabetes patients is seeking its final two participants. MediciNova anticipates top-line data from the ALS trial by the end of next year and is preparing for discussions with the FDA. Results for these trials have not yet been presented.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.